Pegfilgrastim Biosimilars Market Report 2026

The pegfilgrastim biosimilars market size has grown strongly in recent years. It will grow from $1.92 billion in 2025 to $2.04 billion in 2026 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to high cost of originator pegfilgrastim, limited availability of biosimilars, growing cancer patient population, increasing chemotherapy procedures, rising awareness of neutropenia management.

The pegfilgrastim biosimilars market size is expected to see strong growth in the next few years. It will grow to $2.65 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to launch of new biosimilars, increasing adoption in supportive oncology care, expansion of hospital and retail pharmacy networks, government incentives for biosimilar usage, rising investments in stem cell transplantation therapies. Major trends in the forecast period include rising adoption of pegfilgrastim biosimilars in supportive cancer care, expansion of hospital and retail pharmacy distribution channels, increasing focus on reducing chemotherapy-induced neutropenia, growth in hematopoietic and peripheral blood stem cell transplantation applications, rising investments in treatment of chronic and severe congenital neutropenia.

The climbing cancer incidence is set to drive the pegfilgrastim biosimilars market forward. Cancer encompasses disorders marked by uncontrolled abnormal cell growth and spread. Rising cancer prevalence largely stems from aging populations, as advanced age poses the biggest risk for most cancers, with most cases hitting those over 65. Pegfilgrastim biosimilars cut infection risks in chemo patients by spurring white blood cell production. For instance, in October 2025, the National Health Service (NHS), a UK-based government health agency, reported 354,820 new cancer diagnoses in 2023 - 972 daily, up 8,605 from 2022. Therefore, the increased cancer incidence is driving the pegfilgrastim biosimilars market.

Leading companies in the pegfilgrastim biosimilars market are advancing biopharma innovations like high-quality biosimilars to deliver safe, potent, accessible substitutes for original biologics in cancer care. High-quality biosimilars closely mirror reference products in structure, function, safety, and effectiveness. For instance, in February 2023, Fresenius Kabi, a Germany-based healthcare company specializing in pharmaceuticals and medical technologies, launched Stimufend, its first US pegfilgrastim biosimilar. Stimufend wards off and treats chemotherapy-induced neutropenia via a 6 mg/0.6 mL solution in a single-use pre-filled syringe with needle guard. Merging sophisticated biosimilar tech and user-friendly delivery, Stimufend advances access to premium biologic therapies.

In August 2025, Intas Pharmaceuticals Ltd., an India-based biotechnology company, acquired the UDENYCA from Coherus BioSciences, Inc. for an undisclosed amount. With this acquisition, Intas Pharmaceuticals and Accord BioPharma aim to strengthen their position as a global leader in pegfilgrastim, expand their FDA-approved biosimilar portfolio, and enhance patient access to high-quality, flexible treatment options for reducing the risk of infection in cancer patients. Coherus BioSciences Inc. is a US-based, commercial-stage biopharmaceutical company, focused on both biosimilars and innovative immuno-oncology therapies, with a team of industry veterans leveraging deep expertise in biologics development and commercialization.

Major companies operating in the pegfilgrastim biosimilars market are Amgen, Mylan N.V., Sandoz (a Novartis division), Teva Pharmaceutical Industries Ltd., Biocon, Pfizer, Celltrion Healthcare, Coherus BioSciences, Gedeon Richter, Fresenius Kabi, Hetero Labs, Intas Pharmaceuticals, LG Chem, Merck KGaA, Zydus Cadila, Aurobindo Pharma, Apotex Inc., Dr. Reddy's Laboratories, Stada Arzneimittel AG, Shanghai Henlius Biotech, Alvotech, EirGenix, Kye Pharmaceuticals, CinnaGen, Boryung Pharmaceutical, Sinopharm.

North America was the largest region in the pegfilgrastim biosimilars market in 2025. Middle East is expected to be the fastest growing region in the global pegfilgrastim biosimilars market share during the forecast period. The regions covered in the pegfilgrastim biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pegfilgrastim biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the pegfilgrastim biosimilars market by raising costs of imported biologics, raw materials, and formulation technologies. Hospital and retail pharmacies in regions such as North America and Europe, which depend heavily on imports, are most affected. This has increased treatment costs and slowed market penetration. On the positive side, tariffs have stimulated domestic manufacturing, encouraged local R&D, and promoted the development of cost-effective biosimilar alternatives, leading to broader accessibility over time.

The pegfilgrastim biosimilars market research report is one of a series of new reports that provides pegfilgrastim biosimilars market statistics, including pegfilgrastim biosimilars industry global market size, regional shares, competitors with a pegfilgrastim biosimilars market share, detailed pegfilgrastim biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the pegfilgrastim biosimilars industry. This pegfilgrastim biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pegfilgrastim biosimilars are biosimilar drugs designed for use alongside supportive care in patients with non-myeloid cancers. They help prevent or treat infections caused by myelosuppressive chemotherapy by stimulating the production of specific white blood cells.

The main applications of pegfilgrastim biosimilars include chemotherapy treatment, transplantation, and other related uses. Chemotherapy involves the administration of one or more anti-cancer drugs according to a defined treatment protocol. These biosimilars are distributed through hospital pharmacies, retail pharmacies, and mail-order pharmacies.

The pegfilgrastim biosimilars market consists of sales of fulphila, pelgraz, pelmeg, udenyca, ziextenzo, grasustek, fylnetra, and stimufend. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.